Updates in Vaccines, Viral Therapy and Non-Lymphocytic Immunotherapy for Glioblastoma

A key focus of glioblastoma (GBM) management presently revolves around the cancer’s ability to evade and suppress anti-tumor immune response. Therefore, cancer immunotherapy is a critical area in development and investigation with numerous ongoing clinical trials and animal studies. Ranging from vaccines containing tumor-associated antigens or antigen-presenting dendritic cells to viral therapies and immune checkpoint inhibitor antibodies, immunotherapy offers novel therapeutic avenues for GBM as well as other solid and hematogenous cancers. This review provides an overview and update on various significant immunotherapy developments in addition to introducing novel targets for cancer treatmen